CCM
RPTP

Cadence Capital Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Cadence Capital Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,968
Closed -$328K – 704
2013
Q3 		$328K Sell
21,968
-33,406
-60% -$400K 0.01% 568
2013
Q2 		$518K Buy
+55,374
New +$375K 0.02% 344

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Cadence Capital Management's RPTP Position: Q4 2013 in Review

Cadence Capital Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2013, closing a stake of 21,968 shares — an estimated $328K sold.

Cadence Capital Management first reported a position in RPTP in Q2 2013 and held it in 2 quarters. The position peaked at $518K in Q2 2013. 68 funds tracked by Wall St. Rank hold RPTP as of Q4 2013.

  • Cadence Capital Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • Cadence Capital Management sold 21,968 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2013, an estimated $328K.
  • Cadence Capital Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 2 quarters.
  • Cadence Capital Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $518K in Q2 2013.
  • 68 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2013.

Based on Cadence Capital Management's 13F filing for Q4 2013, filed 31 Jan 2014.